DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2015; 140(24): 1831-1834DOI: 10.1055/s-0041-107694 Klinischer Fortschritt Nephrologie © Georg Thieme Verlag KG Stuttgart · New York Dialyse und Nierentransplantation Dialysis and renal transplantation: update 2015 Werner Riegel 1 Medizinische Klinik III, Klinikum Darmstadt GmbH , Bernd Krüger 2 V. Medizinische Klinik, Universitätsklinikum Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg › Author Affiliations Recommend Article Abstract Schlüsselwörter SchlüsselwörterHämodialyse - Peritonealdialyse - Spironolacton - Antikoagulation - Nierentransplantation - Organqualität - Resistance-Index Keywords Keywordshemodialysis - peritonealdialysis - spironolactone - anticoagulation - renal transplantation - organ quality - resistance index Full Text References Literatur 1 Weir MA, Dixon SN, Fleet JL et al. β-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2014; 26: 987-996 2 Ito Y, Mizuno M, Suzuki Y et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014; 25: 1094-1102 3 Zhan L, Hao JB, Ren LS et al. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. Lab Invest 2014; 94: 839-850 4 Vazquez-Rangel A, Soto V, Escalona M et al. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients. Am J Kidney Dis 2014; 63: 1072-1074 5 Shapiro BB, Streja E, Ravel VA et al. Association of height with mortality in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol 2015; 10: 965-974 6 Krummel T, Scheidt E, Borni-Duval C et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize?. Nephrol Dial Transpl 2014; 29: 906-913 7 Lavainne F, Meffray E, Pepper RJ et al. Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. Nephrol Dial Transpl 2014; 29: 1225-1231 8 Di Marco GS, Pavenstädt H, Brand M. Soluble Flt-1 release response to heparin use: implications for dialysis patients. Nephrol Dial Transpl 2014; 29: 1212-1215 9 US Food and Drug Administration (FDA). Eliquis (apixaban) Tablets. www.fda.gov/safety/medwatch/safetyinformation/ucm384790.htm 10 Contreras G, Pagan J, Chokshi R et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol 2014; 9: 1949-1956 11 Guru P, Prakash R, Sheth H et al. Comparison of survival of patients with heart and lung transplants on peritoneal dialysis and hemodialysis. Perit Dial Int 2015; 35: 98-101 12 Paudel K, Fan SL. Successful use of continuous ambulatory peritoneal dialysis in 2 adults with gastrostomy. Am J Kidney Dis 2014; 64: 315-318 13 Farney AC, Rogers J, Orlando G et al. Evolving experience using kidneys from deceased donors with terminal acute kidney injury. J Am Coll Surg 2013; 216: 645-655 14 Benck U, Schnuelle P, Krüger B et al. Excellent graft and patient survival after renal transplantation from donors after brain death with acute kidney injury: a case-control study. Int Urol Nephrol 2015; Oct 26. [Epub ahead of print] 15 Jacobi J, Rebhan D, Heller K et al. Donor acute kidney injury and short-term graft outcome in renal transplantation. Clin Transplant 2014; 28: 1131-1141 16 Naesens M, Heylen L, Lerut E et al. Intrarenal resistive index after renal transplantation. New Engl J Med 2013; 369: 1797-1806 17 Kolonko A, Chudek J, Wiecek A. Initial kidney graft resistance index and the long-term cardiovascular mortality in transplanted patients: a paired grafts analysis. Nephrol Dial Transplant 2015; 30: 1218-1224
